Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2 (LIPOCORT)

University Hospital, Lille

Status: Completed

Conditions: Familial Partial Lipodystrophy Type 2

Treatments: Other: Biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT04845165

2020-A03167-32 (Other Identifier)

2020_50

Details and patient eligibility

About

Familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue. They are associated with a severe metabolic syndrome especially when linked to the mutation of the R482 codon of the LMNA gene (Familial partial lipodystrophy type 2, FPL2). Data in lipodystrophy induced by antiretroviral therapy of HIV suggests an increase in the activity of 11β-hydroxysteroid dehydrogenase type 1 (11bHSD1). This enzyme reactivates cortisone in cortisol in adipose tissues and liver and has associated to obesity and type 2 diabetes mellitus. Hence, the hypothesis is that in patients suffering from FPL2 with the R482 codon mutation of the LMNA gene, there is an increase in the activity of HSD11B1 which could participate to the metabolic phenotype of the disease.

Enrollment: 25 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Familia partial lipodystrophy type 2 (FPL2) with the R482 codon mutation of the LMNA gene
• Social insured
• Ability to give consent

Exclusion criteria

• urinary incontinence or inability to collect urine for 24 hours
• moderate and severe kidney insufficiency
• hepatic insufficiency
• history of hypercortisolism or adrenal insufficiency
• treatment interfering with the cortisol metabolism: taking oral or inhaled glucocorticoids within the last 6 months
• pregnant and lactating woman.

Trial design

25 participants in 1 patient group

Patients with FPL2 genetically confirmed

Description:

patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.

Treatment:

Other: Biopsy